S. Korea’s H2Holdings To Begin Testing Bio-Artificial Liver System In U.S.
This article was originally published in PharmAsia News
Executive Summary
H2Holdings, a South Korean venture, received U.S. FDA permission to begin clinical trials of its HepaPheresis bio-artificial liver system that relies on organs from pigs.